History/Milestones

The following represents the highlights of what the Company has accomplished to date:

• Signed a strategic cooperation and licensing agreement with Atrium Biotechnologies Inc. for the Personal Care and Nutraceutical Industries, Atrium is a privately held subsidiary of the publicly-traded pharmaceutical company Aeterna Laboratories Inc. (TSX:AEL; NASDAQ:AELA collaboration.
• Completed an "in-vitro" study for Canadian Willowherb™ and the bioactive molecule Oenothein-B (isolated from Epilobium angustifolium) effectively killing Propionibacterium acnes, a bacterium that is associated with acne. Patent protection was applied for.
• Johnson & Johnson’s "baby extracare" baby wipes product released to the European market. This marks the first major mass-market release of a product featuring Canadian Willowherb™ as its active ingredient.

• Stiefel Laboratories Inc. of Florida launched Claripel® Crème, a pharmaceutical skin-lightener containing Tyrostat™ .
• Entered into a strategic product development and licensing agreement with Lonza Inc., a leader in the bio-industrial market.
• Applied for patent protection for Fytolastin™ .

• Positive independent trial on human skin demonstrated that Tyrostat™ skin whiteners may effectively reduce the appearance of age spots within 3 weeks of treatment.
• Conducted two in-vivo clinical trials on Tyrostat™. The results showed that Tyrostat™ effectively prevented melanin production (tanning) and that it may be effective as a method of protecting the skin from sun damage.

• Isolated and characterized Oenothein-B, the molecule that has demonstrated the anti-irritant/anti-inflammatory and free radical scavenging properties of Canadian Willowherb™ (Epilobium angustifolium). Applied for patent protection on Oenothein-B.
• Independent clinical trials demonstrated that an extract of the anti-irritant Canadian Willowherb™ acted faster and as effective as hydrocortisone, the US Food and Drug Administration (FDA) approved drug, in reducing the redness of chemically irritated human skin.
• Released the Tyrostat™ line of skin whiteners and an anti-irritant/anti-inflammatory developed from Canadian Willowherb™.
• Fytokem listed on the Alberta Stock Exchange (ASE), now the Toronto Stock Exchange Venture Board (TSXV), and raised $1 million (gross proceeds) through an IPO.
• Company incorporated in 1994 to discover, develop and commercialize the phytochemical agents found in the plants of the northern Canadian prairies. This grew out of one of the founders, Dr. Warren Steck’s, lifelong interest in the commercialization of phytochemicals. Dr. Steck was a former Director General of the Plant Biotech Institute (PBI) for the National Research Council.